Lesson
Build the Neuromuscular Junction Failure
Myasthenia gravis is an autoimmune disorder of postsynaptic neuromuscular transmission. The motor nerve can release acetylcholine normally, yet the end plate cannot translate every impulse into dependable muscle contraction.
- Acetylcholine
- AChR
- MuSK
- LRP4
- Safety factor
The motor nerve supplies a normal chemical signal to the synaptic cleft.
AChR, MuSK, and LRP4 biology determines whether the end plate can translate the signal.
Postsynaptic injury lowers reserve, so contraction fails as activity continues and improves with rest.
Begin at the motor end plate
Acetylcholine crosses the synaptic cleft and activates nicotinic receptors on skeletal muscle. Acetylcholinesterase rapidly terminates the signal so repeated contraction depends on intact release, receptor density, end plate architecture, and recovery.
Separate antibody phenotypes
Most patients have antibodies to the acetylcholine receptor. MuSK antibodies disrupt receptor clustering and junction organization, while LRP4 and other antibodies explain a smaller share. Seronegative disease remains possible when standard assays are negative.
Understand fatigability
Transmission begins with a reduced safety factor. Repeated activation exposes the deficit, producing weakness that worsens with sustained use and often improves with rest.
Keep sensation and cognition distinct
The disorder affects voluntary skeletal muscle rather than sensory nerves, smooth muscle, or thought. Sensory loss, bowel paralysis, or confusion should reopen the differential diagnosis.
Use chemistry where it changes care
Pyridostigmine is a reversible carbamate acetylcholinesterase inhibitor. Its permanently charged quaternary ammonium group limits central nervous system penetration and concentrates its clinical effect at peripheral cholinergic synapses.
Quick check
Lesson
Recognize the Pattern and Protect Breathing
The diagnostic pattern is fluctuating, fatigable weakness, but the first clinical responsibility is to identify bulbar or respiratory compromise that can progress faster than routine outpatient evaluation.
- Ptosis and diplopia
- Bulbar weakness
- Neck flexion
- FVC and NIF
- Impending crisis
Ocular, bulbar, axial, limb, and respiratory weakness fluctuate with use and time.
Wet voice, secretion pooling, choking, and weak cough can precede airway loss.
FVC, NIF, speech, gas exchange, and trajectory matter even when oxygen saturation is normal.
Recognize common presentations
Ptosis, diplopia, facial weakness, nasal speech, chewing fatigue, dysphagia, neck weakness, proximal limb weakness, and shortness of breath can fluctuate over hours and worsen later in the day or with illness.
Find bulbar risk
Weak cough, pooling secretions, wet voice, choking, prolonged meals, nasal regurgitation, and inability to handle saliva signal aspiration and airway risk even before severe limb weakness appears.
Assess ventilation directly
Pulse oximetry can remain normal until late because oxygenation is not the same as ventilatory muscle strength. Serial forced vital capacity, negative inspiratory force, bedside speech and cough, gas exchange, and trajectory guide escalation.
Define crisis operationally
Impending crisis means rapid clinical worsening that may lead to intubation. Manifest crisis is weakness requiring intubation or delaying extubation. The response is monitored respiratory care, not a delayed office medication adjustment.
Protect the differential
Lambert Eaton syndrome, botulism, brainstem disease, motor neuron disease, myopathy, thyroid eye disease, medication toxicity, and functional disorders can overlap. Reflexes, autonomic symptoms, pupils, sensory findings, central signs, and response to activity help separate them.
Quick check
Lesson
Confirm the Phenotype and Search for Thymic Disease
Diagnosis integrates the clinical pattern with antibody testing and neuromuscular physiology. The workup also identifies thymoma and competing conditions because those findings change treatment.
- AChR antibodies
- MuSK antibodies
- Repetitive stimulation
- Single fiber EMG
- Chest imaging
AChR is usually first, followed by MuSK and selected additional testing when suspicion remains.
Repetitive stimulation and single fiber EMG can reveal junction failure.
Chest CT or MRI identifies thymoma and thymic abnormality that change management.
Start with phenotype and antibodies
AChR binding antibodies are the usual first serologic test. If negative and suspicion remains, assess MuSK and selected additional antibodies according to specialist pathways. A positive antibody supports autoimmune MG in the correct clinical context.
Use electrodiagnostic physiology
Repetitive nerve stimulation can demonstrate a decremental response. Single fiber electromyography is highly sensitive for impaired neuromuscular transmission but is not specific enough to replace clinical interpretation.
Use bedside tools narrowly
An ice pack can transiently improve ptosis and support the diagnosis in an ocular presentation. Bedside response does not classify antibody phenotype or exclude central and structural causes.
Image the thymus
Chest CT or MRI evaluates thymoma and thymic abnormality. Thymoma requires surgical evaluation regardless of whether symptomatic control is otherwise adequate.
Build a baseline
Document MG activities of daily living, examination distribution, respiratory and bulbar status, thyroid and autoimmune context, medicine exposures, infection, reproductive plans, and the functional outcomes that treatment should improve.
Quick check
Lesson
Use Pyridostigmine Around Function
Pyridostigmine increases acetylcholine exposure at the neuromuscular junction and can improve strength quickly. It is symptomatic therapy, not a treatment for the pathogenic antibody response.
- Reversible AChE inhibition
- Timing around meals
- Renal elimination
- Muscarinic toxicity
- Cholinergic weakness
Short duration makes dose timing as important as total exposure.
Renal function, response, and muscarinic symptoms define the useful dose.
Diarrhea, sweating, fasciculation, and paradoxical weakness make blind escalation unsafe.
Target the working day
Immediate release doses are often timed before meals or demanding activities because onset and duration are limited. Extended release can support selected overnight or morning goals but has less predictable absorption and does not replace individualized daytime dosing.
Titrate clinically
RxPrep describes a broad adult total daily range from 60 to 1500 mg, often near 600 mg in five or six divided doses. The correct regimen is individualized by response, formulation, tolerability, disease severity, and specialist plan rather than by chasing a memorized maximum.
Respect renal elimination
Pyridostigmine is substantially eliminated unchanged by the kidney. Reduced kidney function can increase exposure, so lower requirements and careful titration may be appropriate.
Recognize muscarinic toxicity
Diarrhea, abdominal cramping, nausea, salivation, sweating, miosis, urinary urgency, and bronchial secretions indicate excess peripheral cholinergic effect. Glycopyrrolate is sometimes used under specialist direction for troublesome muscarinic symptoms.
Recognize nicotinic excess
Fasciculations, muscle cramps, and paradoxical weakness can occur with excess acetylcholinesterase inhibition. Mechanical intestinal or urinary obstruction is a contraindication, and asthma, dysrhythmia, secretion burden, and bradycardia require caution.
Quick check
Lesson
Control Autoimmunity With a Time Horizon
Corticosteroids and steroid sparing immunotherapies reduce autoimmune activity, but their onset and toxicity differ. The plan must bridge current function while protecting long term health.
- Prednisone
- Early worsening
- Azathioprine
- Mycophenolate
- Monitoring
Pyridostigmine and rescue therapy may cover the delay before immune control appears.
Corticosteroids act sooner but can worsen weakness early; steroid sparing drugs can take months.
Function, crisis, infection, organ toxicity, bone, metabolic, and reproductive risks define success.
Use corticosteroids deliberately
Prednisone is effective but may transiently worsen weakness during the first days or weeks, especially with high initial exposure or substantial bulbar disease. High risk initiation may require slower escalation or monitored care.
Select a steroid sparing strategy
Azathioprine, mycophenolate, tacrolimus, cyclosporine, and other immunotherapies have distinct onset, laboratory, interaction, organ toxicity, pregnancy, malignancy, and infection considerations. Choice is patient specific and specialist managed.
Respect delayed benefit
Azathioprine and several alternatives can take months to show meaningful effect. Do not declare failure prematurely or expose the patient to indefinite corticosteroid toxicity without a documented reassessment point.
Build surveillance before treatment
Baseline blood counts, liver and kidney function, infection and vaccination review, reproductive planning, drug interactions, bone and metabolic risk, and product specific testing should be completed before or early in therapy.
Measure both disease and harm
Follow function, bulbar and respiratory symptoms, examination, exacerbations, rescue use, corticosteroid exposure, infection, blood pressure, glucose, bone health, weight, mood, eyes, laboratory toxicity, and patient priorities.
Quick check
Lesson
Match Thymectomy to the Disease
Thymectomy is mandatory to evaluate when thymoma is present and can improve long term outcomes in selected nonthymomatous AChR positive generalized disease. It is not a universal procedure for every antibody phenotype.
- Thymoma
- AChR positive generalized MG
- Age 18 to 50
- Elective stability
- MuSK limitation
A thymic tumor requires surgical evaluation while MG is stabilized.
Younger adults with generalized AChR positive nonthymomatous disease have the clearest benefit.
Elective surgery is safer after respiratory and bulbar function are controlled.
Treat thymoma as its own indication
A thymic tumor requires thoracic surgical and oncology evaluation. Complete resection is pursued when feasible, while MG is stabilized and managed before, during, and after surgery.
Use consensus criteria
Current international guidance supports discussing thymectomy early in nonthymomatous generalized AChR antibody positive MG, particularly from ages 18 through 50, to improve outcomes and reduce immunotherapy burden.
Consider inadequate control
Thymectomy should be strongly considered when a patient with generalized AChR positive disease has an inadequate response to initial immunotherapy or intolerable adverse effects from that therapy.
Operate electively when stable
The procedure should occur when the patient is clinically stable because perioperative bulbar or respiratory weakness increases risk. Preoperative rescue therapy may be used selectively in high risk patients.
Respect phenotype limits
Current evidence does not support thymectomy as routine immune treatment for MuSK, LRP4, or agrin antibody disease. Ocular disease requires individualized specialist discussion rather than automatic extrapolation.
Quick check
Lesson
Treat Myasthenic Crisis as Respiratory Failure
Rapid immunomodulation is only one part of crisis care. Airway protection, ventilatory support, trigger treatment, secretion management, nutrition, thrombosis prevention, and careful medication review determine survival and recovery.
- FVC and NIF
- Intubation
- Plasma exchange
- IV immune globulin
- Precipitating factor
Cough, secretions, FVC, NIF, speech, and trajectory guide airway timing.
Select rapid therapy from phenotype, access, hemodynamics, kidney function, thrombosis risk, and speed.
Infection, aspiration, surgery, treatment interruption, and medication exposure must be corrected.
Do not wait for arterial hypoxemia
Serial respiratory mechanics, weak cough, secretion burden, bulbar function, gas exchange, work of breathing, speech, and clinical trajectory should drive ICU and airway decisions. Elective intubation is safer than a crash airway.
Choose rapid immune rescue
Plasma exchange and IV immune globulin are accepted short term treatments for crisis and severe exacerbation. Plasma exchange often acts faster and is particularly useful in MuSK disease, while vascular access, hemodynamics, kidney function, thrombosis risk, infection, and availability shape selection.
Treat the trigger
Respiratory infection, aspiration, surgery, pregnancy related change, medication exposure, treatment interruption, and uncontrolled disease are common contributors. Culture and antimicrobial choices must account for MG medication cautions.
Handle pyridostigmine thoughtfully
During intubated crisis, acetylcholinesterase inhibition is often reduced or held because secretions complicate airway care. It is restarted and titrated as strength and extubation readiness improve under specialist direction.
Plan extubation beyond one number
Respiratory mechanics, cough, secretion clearance, bulbar strength, gas exchange, fatigue over time, and trigger control must align. A single improved measurement does not guarantee durable airway protection.
Quick check
Lesson
Lower Pathogenic IgG Through FcRn
FcRn blockers interrupt IgG recycling, accelerating reduction of circulating IgG, including pathogenic autoantibodies. Products differ in antibody requirements, route, schedule, age, and product specific safety.
- Efgartigimod
- Rozanolixizumab
- Nipocalimab
- IgG reduction
- Vaccination and infection
Less FcRn rescue sends more IgG toward degradation.
Efgartigimod, rozanolixizumab, and nipocalimab differ by phenotype, age, route, and schedule.
Review active infection, live vaccines, treatment cycles, and Fc containing therapies.
Understand the target
The neonatal Fc receptor rescues IgG from lysosomal degradation. Blocking FcRn lowers circulating IgG without directly depleting B cells, so effect and infection risk must be monitored across treatment cycles.
Place efgartigimod accurately
Efgartigimod alfa is available as intravenous Vyvgart and subcutaneous Vyvgart Hytrulo. FDA expanded the adult generalized MG indication in May 2026 beyond the older AChR positive restriction. Current labeling should be checked before every prescribing decision.
Place rozanolixizumab accurately
Rystiggo is approved for adults with AChR or MuSK antibody positive generalized MG. It is administered by a healthcare provider as a weight based subcutaneous infusion once weekly for six weeks, with later cycles based on clinical evaluation.
Place nipocalimab accurately
Imaavy is approved for AChR or MuSK antibody positive generalized MG from age 12. It uses a 30 mg/kg intravenous loading dose, then 15 mg/kg two weeks later and every two weeks, with observation for infusion and hypersensitivity reactions.
Build shared class safety
Delay treatment during active infection when the label directs, review age appropriate vaccines before treatment, avoid live vaccines during IgG lowering treatment, and monitor for reduced effectiveness of immunoglobulin products or Fc containing monoclonal therapies. Rystiggo also carries an aseptic meningitis warning.
Quick check
Lesson
Block Terminal Complement Without Underestimating Infection
Terminal complement inhibition can prevent membrane attack complex injury at the AChR positive neuromuscular junction. The benefit comes with a distinctive risk of rapidly fatal meningococcal infection that vaccination cannot eliminate.
- Eculizumab
- Ravulizumab
- Zilucoplan
- C5
- Meningococcal REMS
Current US MG labels for eculizumab, ravulizumab, and zilucoplan are phenotype specific.
Vaccination, urgent prophylaxis when required, REMS, and a safety card form one prevention system.
Vaccination cannot eliminate meningococcal risk, so compatible illness needs immediate evaluation.
Match the antibody phenotype
Eculizumab is approved for AChR positive generalized MG from age 6, ravulizumab for AChR positive adults, and zilucoplan for AChR positive adults. These labels do not establish benefit for every seronegative or MuSK phenotype.
Block C5
These therapies prevent terminal complement activation and membrane attack complex formation. Eculizumab and ravulizumab are intravenous monoclonal antibodies, while zilucoplan is a once daily weight based subcutaneous peptide inhibitor.
Complete meningococcal prevention
Use current ACIP guidance for MenACWY and MenB vaccination, ideally at least two weeks before the first dose. If urgent treatment cannot wait, follow the label for antibacterial prophylaxis and vaccinate as soon as possible.
Teach residual risk
Vaccination reduces but does not eliminate meningococcal risk. Fever, severe headache, neck stiffness, photophobia, confusion, rash, myalgia, or rapidly progressive illness requires immediate evaluation. Product REMS and safety card requirements must be followed.
Protect the pancreas with zilucoplan
Obtain baseline lipase and amylase. Pancreatitis and pancreatic cysts have been reported, so new persistent abdominal pain, nausea, or vomiting requires evaluation and suspected pancreatitis requires treatment interruption while assessed.
Quick check
Lesson
Prevent Avoidable Worsening Across the Care Plan
Medication cautions in MG are clinically important, but most are not automatic universal contraindications. The right response is to identify the strength of association, necessity, safer alternatives, dose, route, and monitoring capacity.
- Medication review
- Magnesium
- Antibiotics
- Pregnancy
- Anesthesia
Telithromycin, fluoroquinolones, IV magnesium, and other exposures do not carry identical evidence.
Neurology, obstetrics, anesthesia, pharmacy, and surgery need one shared MG plan.
Rapidly worse swallowing, cough, head control, or breathing requires urgent care.
Use the caution list precisely
Telithromycin carries the strongest warning and should not be used. Fluoroquinolones have an FDA boxed warning for worsening MG. Aminoglycosides, macrolides, beta blockers, procainamide, botulinum toxin, D penicillamine, selected antipsychotics, neuromuscular blockers, and other agents require avoidance or careful benefit and risk review according to the situation.
Treat magnesium as route and dose dependent
Intravenous magnesium can significantly impair neuromuscular transmission and may be dangerous. Oral replacement still requires a reason, dose, kidney function review, and symptom monitoring rather than a blanket assumption that every trace exposure is forbidden.
Plan pregnancy before it begins
Oral pyridostigmine is usually first line for symptom control in pregnancy. IV cholinesterase inhibitors can provoke uterine contractions. Immunotherapy and targeted therapy require product specific reproductive review, while thymectomy is generally deferred until after pregnancy.
Coordinate anesthesia
MG changes sensitivity to nondepolarizing neuromuscular blockers and can alter response to other anesthetic drugs. The anesthesia team needs current respiratory and bulbar status, antibody phenotype, medicine timing, prior crisis history, and a postoperative ventilation plan.
Give an escalation script
Patients should seek urgent care for rapidly worse speech, swallowing, cough, head control, breathing, or generalized weakness. They should not stop essential therapy or start a new prescription, OTC product, supplement, or infusion without checking the MG plan.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 108 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- International Consensus Guidance for Management of Myasthenia Gravis, 2020 Update
- Guideline for the Management of Myasthenic Syndromes
- Myasthenia Gravis Foundation of America, Cautionary Drugs
- FDA, Imaavy Prescribing Information
- FDA, Zilbrysq Prescribing Information
- FDA, Rystiggo Prescribing Information
- FDA, Pyridostigmine Prescribing Information
- FDA Orphan Drug Database, Efgartigimod 2026 Indication Update